We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Allogene’s Q2 Earnings Top, Sales Lag
Allogene incurred loss of 53 cents per share in second-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of 55 cents. The bottom line was flat year over year.
The company recorded revenues of $0.04 million during the quarter, missing the Zacks Consensus Estimate of $0.95 million. The company did not record any revenues in the year-ago quarter.
Quarter in Detail
Research & development (R&D) expenses were $52.3 million, up 10.6% from the year-ago quarter.
General and administrative (G&A) expenses increased 18.4% year over year to $18.8 million.
The company had $913.2 million in cash, cash equivalents and investments as of Jun 30, 2021, compared with $964.2 million at the end of Mar 31, 2021.
2021 Guidance Maintained
Allogene maintained its previous guidance for operating expenses for 2021, which is expected to be between $300 million and $330 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
At this time, Allogene Therapeutics has an average Growth Score of C, a grade with the same score on the momentum front. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Allogene’s Q2 Earnings Top, Sales Lag
Allogene incurred loss of 53 cents per share in second-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of 55 cents. The bottom line was flat year over year.
The company recorded revenues of $0.04 million during the quarter, missing the Zacks Consensus Estimate of $0.95 million. The company did not record any revenues in the year-ago quarter.
Quarter in Detail
Research & development (R&D) expenses were $52.3 million, up 10.6% from the year-ago quarter.
General and administrative (G&A) expenses increased 18.4% year over year to $18.8 million.
The company had $913.2 million in cash, cash equivalents and investments as of Jun 30, 2021, compared with $964.2 million at the end of Mar 31, 2021.
2021 Guidance Maintained
Allogene maintained its previous guidance for operating expenses for 2021, which is expected to be between $300 million and $330 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
At this time, Allogene Therapeutics has an average Growth Score of C, a grade with the same score on the momentum front. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.